Eli Lilly to Offer Breakthrough Migraine Drug for Free
*By Michael Teich*
[Twelve percent](https://migraineresearchfoundation.org/about-migraine/migraine-facts/) of the U.S. population may suffer from chronic migraines, but many Americans don't appreciate the impact, said president of Lilly Bio-Medicines Christi Shaw.
"These patients need to be treated seriously. This is a neurological disorder," Shaw said Friday in an interview on Cheddar.
Eli Lilly ($LLY) just received clearance from the FDA for its latest drug, and it could change the lives of the 39 million Americans suffering from migraines, according to Shaw.
The treatment, Emgality, is a monthly, self-administered injection that will help patients cut the frequency of their migraines in half, she said.
Shaw said that many Americans conflate headaches and migraines, and so they often dismiss their pain. They key difference is that the symptoms of a migraine disrupt one's ability to function optimally through the day. That doesn't happen with a more commonplace headache. And a stigma contributes to the glaring statistic that only about 10 percent of those suffering from migraines take prescription drugs for prevention, Shaw said.
Emgality comes with a serious price tag: $6,900 a year, or $575 a month. But Eli Lilly is offering commercially insured patients up to 12 months of the drug for free. It's among the latest efforts from the industry to offer consumers some relief from surging drug costs.
Competitors Amgen ($AMGN) and Teva ($TEVA) have already unveiled new migraine treatment drugs.
For full interview [click here](https://cheddar.com/videos/eli-lilly-gets-fda-approval-for-new-migraine-treatment).
Neil Young has come up with an ultimatum for Spotify: his music or Joe Rogan’s podcast. This comes over concerns that the podcast is spreading COVID-19 vaccine misinformation to its listeners. "The Joe Rogan Experience," which is exclusive to Spotify, is currently the number one streamed podcast on the platform.
Commercial and residential buildings account for 13% of carbon emissions in the U.S., according to the EPA, and one company says it has a solution. Runwise says it has updated the boiler and heating systems of thousands of buildings, and that its technology not only lowers carbon output but also saves landlords money. Lee Hoffman, Co-Founder and COO of Runwise, joined Cheddar Climate to discuss.
Jo Ruxton, Founder of Ocean Generation, joins Cheddar Climate, where she explains the threat that plastic pollution poses to marine life, but elaborates on why we shouldn't be looking to ban plastic entirely. Ruxton also discusses her biggest takeaways while producing the film ‘A Plastic Ocean.'
President Joe Biden's Build Back Better deal seems all but finished after months of Democratic infighting and the Senate's deadlock over certain provisions. But Biden mentioned during a press conference marking his first year in office that 'chunks' of the bill could be passed. Is that enough motivation to force Democrats to rally around certain parts of the bill - especially those that focus on climate and green energy? Andrew Freedman, Energy and Climate Reporter at Axios, joins Cheddar Climate to discuss whether Senate Democrats will be able to rally around climate provisions, if the idea of passing Build Back Better in 'chunks' is doable, and more.
Anyone who remembers the 70s and 80s will probably remember acid rain. Industrial emissions acidified precipitation around the globe, which killed forests and crops, rendered lakes inhospitable, corroded buildings, and exacerbated human health problems.
But anyone who follows environmental news will be surprised to learn this: we solved it! Countries came together to limit acid rain-causing emissions, eliminating the problem altogether.
…kind of. Acidic precipitation may not be a thing of the past after all.
Natalie Ginsberg, Global Impact Officer, MAPS, joins Cheddar Reveals to discuss MAPS organization and its current initiatives and their work to get FDA approval for MDMA to treat PTSD.
Kelsey Ramsden, Co-Founder, President & CEO, Mind Cure Health, joins Cheddar Reveals to break down what 'psychedelic therapy' could look like once it's legalized and how Mind Cure Health is using AI to help treat everything from addiction to depression.
On this episode of Cheddar Reveals, Natalie Ginsberg, Global Impact Officer, MAPS, discusses the MAPS organization and its current initiatives and their work to get FDA approval for MDMA to treat PTSD; Kelsey Ramsden, Co-Founder, President & CEO, Mind Cure Health, breaks down what 'psychedelic therapy' could look like once it's legalized and how Mind Cure Health is using AI to help treat everything from addiction to depression; Cheddar gets a look at Curiosity Stream's 'Pain, Pus and Poison.'
